This document discusses the development of the biopharmaceuticals industry in India. It provides an overview of the characteristics and growth of the Indian biopharma market, which is valued at over $4 billion and growing 20-25% annually. It also outlines India's advantages for global R&D, including a skilled workforce, lower costs, and efficient clinical trials. The upcoming biosimilars opportunity from patent expiries is highlighted as a major driver. Challenges include financing difficulties and developing human resources excellence. Overall, the biopharma sector is one of India's fastest growing industries.
Genetic engineering and pharmaceutical production in microorganismsNawfal Aldujaily
Role Of Genetic Engineering In Improvement Of Pharmaceutical Production of Microorganisms lecture in department of biology.faculty of science.University of Kufa
Genetic engineering and pharmaceutical production in microorganismsNawfal Aldujaily
Role Of Genetic Engineering In Improvement Of Pharmaceutical Production of Microorganisms lecture in department of biology.faculty of science.University of Kufa
Brief Profiles of 50 Bio-entrepreneurs of India along with their company information. Biotechnology in India is in nascent stage. India has around 800 biotech companies out of which only 50 are presented here. They represent all the waves of biotech growth in India.
Contents
1. Insulin Molecule
2. Effect of Insulin in Body
3. History of Insulin
4. Recent Trends in Insulin Productions and Types
4.1 Animal Insulins
4.2 Long-Acting Insulins
4.3 Human Insulins
4.4 Insulin Analogues
4.5 Biosimilar Insulins
5. Insulin Production (Chain A and Chain B Method)
5.1 Upstream Processing
5.2 Downstream Processing
6. The Proinsulin Process
7. Insulin Available in Market with Different Brand Names
8. References
This ppt explains about molecular farming, history of molecular farming, importance, basic process underlying it, its application in agriculture and its limitations
The Government of India, through an array of programs and initiatives, offers funding for technology development, from early-stage development to full-scale commercialization to prioritize innovative R&D and promote indigenous technology development. A number of national agencies i.e. Department of Biotechnology (DBT), Department of Science and Technology (DST), Department of Scientific & Industrial Research (DSIR), Council of Scientific & Industrial Research (CSIR), Ministry of Micro Small Medium Enterprises (MSME), National Research Development Corporation (NRDC), Defence Research & Development Organization (DRDO), Technology Information, Forecasting and Assessment Council (TIFAC), etc. have been supporting biotech companies as well as academia in various areas of biotechnology with a view to facilitate accelerated technology development.
Several international India-specific Grand Challenges i.e. Wellcome Trust, Bill & Melinda Gates Foundation, Grand Challenges Canada, Millenium Alliance and bilateral/multi-lateral programmes with other countries also support innovative technology development in India.
Brief Profiles of 50 Bio-entrepreneurs of India along with their company information. Biotechnology in India is in nascent stage. India has around 800 biotech companies out of which only 50 are presented here. They represent all the waves of biotech growth in India.
Contents
1. Insulin Molecule
2. Effect of Insulin in Body
3. History of Insulin
4. Recent Trends in Insulin Productions and Types
4.1 Animal Insulins
4.2 Long-Acting Insulins
4.3 Human Insulins
4.4 Insulin Analogues
4.5 Biosimilar Insulins
5. Insulin Production (Chain A and Chain B Method)
5.1 Upstream Processing
5.2 Downstream Processing
6. The Proinsulin Process
7. Insulin Available in Market with Different Brand Names
8. References
This ppt explains about molecular farming, history of molecular farming, importance, basic process underlying it, its application in agriculture and its limitations
The Government of India, through an array of programs and initiatives, offers funding for technology development, from early-stage development to full-scale commercialization to prioritize innovative R&D and promote indigenous technology development. A number of national agencies i.e. Department of Biotechnology (DBT), Department of Science and Technology (DST), Department of Scientific & Industrial Research (DSIR), Council of Scientific & Industrial Research (CSIR), Ministry of Micro Small Medium Enterprises (MSME), National Research Development Corporation (NRDC), Defence Research & Development Organization (DRDO), Technology Information, Forecasting and Assessment Council (TIFAC), etc. have been supporting biotech companies as well as academia in various areas of biotechnology with a view to facilitate accelerated technology development.
Several international India-specific Grand Challenges i.e. Wellcome Trust, Bill & Melinda Gates Foundation, Grand Challenges Canada, Millenium Alliance and bilateral/multi-lateral programmes with other countries also support innovative technology development in India.
Hi all, with the rigorous secondary research for almost one month helped me to understand basic things about biosimilars and made me do this presentation. Hope u will appreciate it while going through it. thanks.
If anyone in need of this presentation, pls.put ur emial ID in comment box. will be sharing. and please share your thoughts about the presentation. i will be more thankful.
Opportunities of BDS in Pharmaceutical Industries.pptxDr. Manoj Kumbhare
India is the second-largest pharmaceutical market in Asia. ... A BDS graduate can have various job roles available in this sector: Principal Investigator, Co-investigator, Medical Advisor, Drug Developer, Regulatory Affairs Manager or even a Clinical Research Physician.
Career opportunities in the clinical research field are many and varied, with employment settings ranging from pharmaceutical and biotechnology, to medical device companies, contract research organizations, hospitals, educational institutions, independent contractors and more.
Many professionals with a strong science or healthcare related background — such as nurses, pharmacists, medical technologists, physicians and more — are well-positioned to join the clinical research field. Here are 10 career paths in the field.
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Bhaswat Chakraborty
This presentation describes Identification & differentiation of Protocol deviation & violation; Different methods of RCA & best suitable method for Multiregional Clinical Trial; CAPA management and CAPA application to other trial sites/CRO/SMO/ Country that is involved in same trial (Strategic Management and application of CAPA in MRCT)
This presentation gives effective solutions to outliers issue in bioequivalence trials. It described what would be acceptable to Regulatory agencies as well as some new approaches.
Equivalence approches for complex generics DIA 11 april 2019 Bhaswat Chakraborty
This is a workshop that i gave a few days ago on bioequivalence of complex generics like peptides, polymers, liposomes, colloids, ophthamic and topical produtcts.
Clinical trials that are needed for efficacy & safety evidence of Medical devices include feasibility (pilot) and Pivotal trials. An extended battery of preclinical trials are also needed for high risk devices.
Writing Science papers for for publication requires something more thatn creativity. Target journals, content organization, wrting style, elegance and referencing are equally important.
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyBhaswat Chakraborty
NDAS and BLAs cannot be authoritatively reviewed these days until experts from different disciplines act together like a team. This presentation give some foundational points and an illustrative example in that regard.
Teaching by stories, anecdotes and historical facts sept 25 2018Bhaswat Chakraborty
Many difficult principles in science and humanities can be taught best by a story (of its discovery), by an anecdote or some historical facts about them.
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsBhaswat Chakraborty
PG Pharmacy programs are more focused and professionally oriented than the undergraduate counterpart. Many soft skills are required along with the curricular competence for excellence at the PG level.
Scientific integrity calls for some basic originality. Plagiarism can destroy this original creativity and ideation. This presentation defines plagiarism (stealing from others' works) and some of the creative and systematic remedies.
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Bhaswat Chakraborty
Data integrity can be implemented using several approaches. One of the most effective ways to implement DI is a risk based approach. The speaker elaborates this.
There are several dimensions in Pharmaceutical ethics -- Practice-, research- and community oriented. This presentation mainly deals with Clinical research oriented Ethics.
Young pharmaceutical scientists are and can get involved in all aspects of new drug discovery and development. They have to be appropriately qualified, trained and experienced though,
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
High variability in PK can be a characteristic of certain drug products which require different from ordinary strategies and study designs for establishing bioequivalence.
High variability in PK can be a characteristic of certain drug products which require different from ordinary strategies and study designs for establishing bioequivalence.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Development of Biopharmaceuticals Industry in India
1. DEVELOPMENT OF
BIOPHARMACEUTICA
LS INDUSTRY IN
INDIA
Dr. Bhaswat S. Chakraborty
Sr. VP & Chair, R&D Core Committee
Cadila Pharmaceuticals Ltd.
Presented at Industrial Research in Development
of Biopharmaceuticals, a DSIR Workshop, AMA
Centre, Ahmadabad, February 24, 2015
1
2. CONTENTS
Biotech world & Indian Biotech Pharmaceuticals
Some characteristics of Indian Biopharma
Favorable environment for Global R&D labs set up in India
Why India
Indian Labs & CROs
MNC R&D Labs
Opportunities available – upcoming trends
The patent cliff
Biosimilars opportunity
Bottlenecks & Challenges
Various issues
Conclusions
2
4. INDIAN BIOPHARMA
MARKET
Pharmaceutical and health
biotechnology is one of India’s fastest
growing sectors
Biopharmaceuticals account for 64% of
the Indian biotech industry
Valued at >4 Bn USD
Growing ~20-25% rate per annum
Consists of vaccines, bio-similars,
therapeutics, diagnostics, regenerative
medicines and medical technology
Vaccines and bio-similars constitute
the largest component of the
Indian bio-pharma segment 4
5. INDIA: A MAJOR SUPPLIER OF
VACCINES TO UNICEF
Polio-free India one of the 'most impressive accomplishments'
ever – Bill Gates, January 2015
5
6. CHARACTERISTICS OF
INDIAN BIOPHARMA
INDUSTRY
Growth in India is primarily export-driven
Export sales are rising at annual rate of 47%
Domestic sales have risen only up to 6% per
Vaccines are the largest and fastest-growing sector
Currently account for about 43% of India's total
biopharmaceutical sales
Cf. 16% for diagnostics and 13% for therapeutics
Industry growth is concentrated in a small number of
companies
~30 companies account for majority of sales
Led by Biocon, Serum Institute, Zydus, Panacea Biotec...
And India-based subsidiaries of MNCs 6
7. CHARACTERISTICS OF
INDIAN BIOPHARMA
INDUSTRY..
Indian companies manufacture wide range of
biopharmaceuticals
Iclude recombinant insulin, EPO, G-CSF, recombinant
hepatitis-B vaccine, streptokinase, interferon α-2b, rituximab,
and anti-EGFR & anti –VEGF MAb products..
Indian biopharmaceutical R&D is increasing rapidly
Since 2003, the R&D budgets of the top 10 Indian
pharmaceutical companies have more than doubled
7
8. WHY INDIA
The presence of a highly skilled, English speaking workforce of
over 8.5m qualified scientists coupled with a large network of
investigators
A feeder system of 314 medical & a >1000 pharmacy colleges, with
our 35,000 students graduating every year
Nearly 700,000 hospital beds and the largest number of USFDA
approved facilities outside the US
Lower set-up costs
Access to a large and genetically diverse patient pool with
comparatively lower treatment costs than US and Europe
One of the fastest subject recruitment rates globally (c.3x-4x the
global average), with 40-50% lower screen failure and dropout
rates compared to the global averages
Favorable government policy to continue to develop a favorable
regulatory environment
8
9. ADVANTAGE INDIA
Cost advantage
Manufacturing capabilities
Enhancement of vaccine portfolios
Biosimilars
CROs & clinical trial expertise
Recruitment efficiency
Regulatory efficiency
Reliable contract research and mfg.
9
10. ALREADY EXISTING
CAPABILITIES
About 20 companies in India are already developing
bio-similars.
~25 recombinant therapeutics available in India and
15 of them are manufactured within the country.
~50 brands are commercialized in the country by
leading companies such as Biocon, Shantha, Reliance
Life Sciences, Wockhardt and Intas .. includes MNCs
like Novo Nordisk, GSK, Eli Lilly ,,,
Approximately 72 recombinant drugs are currently
undergoing different stages of clinical trials 10
12. INDIAN CROS
India has >70 active CROs engaged in BE & Clinical trials
Mostly Phase II-IV trials including stats & rep[ort writing,
pre- and post approval services
Top Players
Quintiles, PPD, Paraxel
Siro Clinpharm, GVK Bio, Lamda Therapeutics, Inverika
Excellent reputation in protecting clients’ IPR (unlike many
other countries)
Follow international standards in professionalism, accuracy,
precision in output through regulatory and institutional bodies
Indian CROs are good in developing activity metrics
market evolution, market analysis, develop relations with decision
makers to get comprehensive and reliable predictions etc.
Still highly cost attractive
12
16. MNCS BILATERAL R&D WITH
INDIAN COS.
Merck established discovery sourcing deals
with Advinus in 2006 for metabolic-disorder drugs
with Nicholas Piramal in 2007 for oncology drugs
with and Orchid in 2008 for antibacterial compounds
Eli Lilly has had similar agreements for collaborative
approach across several therapeutic areas
with Nicholas Piramal in 2007
with Suven Life Sciences in 2008
with and Zydus Cadila in 2009
with Jubilant in 2008
GlaxoSmithKline with Dr. Reddy’s for cardiovascular,
diabetes, oncology, gastroenterology and pain management
therapeutics 16
17. STRUCTURING RELATIONSHIPS FOR
VALUE CREATION BY INDIAN
COMPANIES
Build
Nothing like it
Strategic acquisitions
Acquisition of assets in a strategy to increase capabilities
and drive scale.
Joint ventures
Accompanied by strategic stakes with nascent and sub-
scale companies
Customer-supplier relationships
To secure capacity, test delivery capabilities and consider
acquisition or joint venturing
17
18. UPCOMING TRENDS: THE PATENT
CLIFF
A major driver of Indian Biopharma Industry
Many companies are planning to diversify into
biosimilars and get into joint ventures for mfg
etc.
Indian biotech can offer all areas of strength
especially in collaborative efforts
Discovery, research and development, support
activities, marketing, and lobbying are other
opportunities
The humanitarian value is huge
The returns are huge as well 18
21. The 2012–2019 patent cliff is highlighted in yellow
FOR THE TOP TEN SELLING
BIOLOGICS
21
Calo-Fern´andez B et al (2012) Pharmaceuticals 2012, 5, 1393-1408
22. A GENERAL STRATEGY DIAGRAM FOR A
SUCCESSFUL ENTRANCE INTO
BIOSIMILARS MARKET
22
Calo-Fern´andez B et al (2012) Pharmaceuticals 2012, 5, 1393-1408
The requirement for key capabilities varies
with the market maturity: from brand-driven in
short term to price-driven in long term
23. Inserted subfigures are Pfizer’s biosimilar capabilities
before the acquisition of Wyeth and the contributions of this
deal
ESTABLISHING THE STRATEGIC
DEALS
23
24. Konde V. (2009) Journal of Commercial Biotechnology Vol. 15, 3, 215–226
INDIAN BIOTECH
COMPANIES
24
25. Company Products/technologies/services in the market
Business
model
Main sector
Advinus Theraputics,
Bangalore and Pune
Metabolic disorders, inflammatory diseases, neglected
diseases
Hybrid
Avestha, Bangalore
Agbiotech and transgenics, biosimilars Vertical
Bharat Biotech International,
Hyderabad Recombinant drugs, cardiovascular diseases, vaccines Product
Bhat Bio-Tech India,
Bangalore
Recombinant proteins, diagnostic markers Hybrid
Bharat Serums and Vaccines,
Mumbai Plasma derivatives, monoclonals, hormones, serums.. Product
Biocon, Bangalore Industrial enzymes, recombinant protein therapeutic
products and human growth hormone
Vertical
Biological E., Hyderabad Diagnostics, combination vaccines, antitetanus and
antisnake venom sera
Vertical
Dr Reddy's Laboratories,
Hyderabad
Infectious and parasitic diseases, oncology, immune
disorders, endocrine, nutritional and metabolic
diseases, ..
Vertical
Gennova Biopharmaceuticals,
Pune
Hi-tech molecules in nephrology, oncology and
cardiology segment
Product
Indian Immunologicals,
Hyderabad
Pediatric and childhood vaccines, DNA-based vaccines,
animal- and human-health products
Product
Indian biotechnology database (http://www.indianbiotech.com/in/db/index.php).
25
29. GENERAL CHALLENGES &
BOTTLENECKS IN INDIA
Highly competitive environment with multiple small sized CROs
Perceived data quality issues in the light of recent blacklisting of
certain principal investigators for fraudulent data
With a positive of overall track record, this perception is likely
to diminish
Decreasing quality of infrastructure, as the tier-one cities in India
become saturated with CROs
There is a need to consider tier-two cities that remain
untapped and also offer a greater pool of treatment naïve
patients
Regulatory challenges in gaining approval for clinical trials
The Indian Government has initiated a multi-billion dollar
process to streamline the regulatory environment
Excellence in human resources is still a challenge
29
30. FINANCING FOR INDIAN
BIOTECH
Some banks help
e.g. Yes Bank: “is philosophically committed to support the
growth of the Indian Biotechnology Sector (so far ~ $1 billion)”
But, in general, money for biotechnology is not easy to come by
Don’t have many venture capital funds in this sector,
largely because it is knowledge intensive and because the
regulatory pathway is not very clear to the common investor
Location helps
Biotech in India is clustered in Bangalore and Hyderabad
(~39% of the total revenue)
Like the San Francisco & Boston in US, they have some of
India’s best research institutions and universities
30
31. LOOKING FORWARD: NATIONAL
BIOTECH DEVELOPMENT
STRATEGY
With DBT's budget to >$300 mn USD annually, this
program is promoting following areas:
The establishment of more university-linked
research centers, with facilities and teaching
standards of international quality.
The rapid expansion of biotech-related PhD and
postdoctoral programs.
Incentives for the repatriation of Indian-born
scientists currently working abroad.
Support for academic laboratory and private
biotech partnerships 31
32. CONCLUDING REMARKS
Health/pharmaceutical biotechnology is one of India’s fastest
growing sectors
India has innovative as well as biosimilar biotech capabilities
Indian biotech companies are growing at ~20-25% rate per
annum
Biologics patent cliff offers Indian companies a huge opportunity
Capability-benchmarking is the key for any company planning to
generate value from the biologics patent cliff
Entering biosimilars market is facilitated by acquiring or
developing R&D, manufacturing, supporting activities, marketing
or lobbying
India has >70 active CROs engaged in BE & Clinical trials which
are cost effective, professional, IPR-sensitive and offer high
quality services
Steep competition among CROs, quality of data, financing, and
excellence in human resources are major challenges
32